QTIWWNasdaqElectromedical & Electrotherapeutic ApparatusUS GAAP · USD

QT Imaging Holdings, Inc

QT Imaging Holdings, Inc. develops and commercializes the QT Breast Scanner, a breast imaging system used in medical settings for screening and diagnostic workflows. The company is based in the United States and operates through a mix of direct sales and distribution partners, with products, software, accessories, and related services tied to its imaging platform.

Revenue18.9m USD
+287.9 %y/y
Operating profit (EBIT)-4.4m USD
+63.6 %y/y
EBIT margin-23.4%
+226.1 ppy/y
Net income-21.1m USD
−134.6 %y/y
Free cash flow-9.1m USD
+10.3 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-20-1001020m USD2021: EBIT -1.1 m USD20212022: 0.00 m USD2022: EBIT -4.3 m USD20222023: 0.04 m USD2023: EBIT -5.0 m USD20232024: 4.9 m USD2024: EBIT -12 m USD20242025: 19 m USD2025: EBIT -4.4 m USD202519-4.4
RevenueOperating profit (EBIT)

Business

Share of revenue
Breast imaging systems70 %

QT Breast Scanner hardware used for breast imaging and screening workflows.

Software and cloud subscriptions10 %

Software and cloud-based platform access tied to scanner operation and use.

Accessories and related products10 %

Scanner accessories and other product add-ons sold with the imaging system.

Training services5 %

Customer training for operators and clinical staff using the QT platform.

Maintenance and support services5 %

Ongoing servicing, maintenance, and related support for installed systems.

Products

Reported · share of revenue
99.1%FY2025100 %
  • Products99.1 %
  • Services0.9 %

Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

Customers are hospitals, radiology centers, clinics, and other medical providers that use breast imaging equipment in clinical workflows. The company also sells through distributors and sales agents, including exclusive arrangements in the U.S. and selected international markets, which broadens access to end users while keeping direct sales optional.

Hospitals

Buy QT Breast Scanners for inpatient and outpatient breast imaging workflows.

Radiology centers

Purchase scanners to expand breast imaging capacity and diagnostic offerings.

Clinics and medical practices

Use the system for breast screening and referral-based diagnostic imaging.

Distributors and sales agents

Resell, lease, or rent the scanners and help reach local healthcare buyers.

Government and defense customers

Buy through designated territories such as U.S. Department of Defense sites.

Strategy

The company’s strategy is to commercialize the QT Breast Scanner through product innovation, clinical adoption, and partner-led distribution. It also emphasizes internal manufacturing capability and strategic manufacturing partnerships to support broader scale-up and market access.

Drive clinical adoption of the QT Breast ScannerShort term

The business depends on hospitals and radiology centers accepting a new imaging platform.

Expand distribution partnershipsShort term

Partner channels help reach buyers faster than a direct-only sales model.

Improve product and software capabilitiesMedium term

Imaging quality, usability, and analytics support differentiation and repeat use.

Scale manufacturing and service deliveryMedium term

Broader commercialization requires reliable production, fulfillment, and support.

Geography

QT Imaging is centered on the U.S. market, where its distribution agreement covers the United States and U.S. territories, while the company retains the ability to sell elsewhere globally. The reports also reference planned expansion into other regions and a Saudi Arabia distribution agreement, indicating an early international commercialization footprint.

Risks

QT Imaging faces the risks typical of an early-stage medical device company, including limited operating history, adoption uncertainty, and the need for regulatory and clinical acceptance. Its partner-led sales model, debt obligations, and dependence on trained radiologists and suppliers add execution risk, while product, IP, and data-security issues can affect commercialization and trust.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Market acceptance of the QT Breast Scanner1Capital and debt repayment risk2Regulatory and product clearance risk3Dependence on distribution partners5Intellectual property protection6
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Market acceptance of the QT Breast ScannerImpact: HighLikelihood: High

    Revenue depends on buyers adopting a new imaging platform at acceptable prices.

    ExposureHospitalsClinicsRadiology centers
  2. Capital and debt repayment riskImpact: HighLikelihood: High

    The company must fund operations and meet debt cash obligations as they come due.

    Exposure: Liquidity and financing capacity

  3. Regulatory and product clearance riskImpact: HighLikelihood: Medium

    Additional FDA clearances may be needed for current and future products.

    Exposure: Medical device approvals

  4. Training and workflow adoption by radiologistsImpact: High

    Customers need trained professionals to review and use the images effectively.

    Exposure: Clinical end users and interpreting physicians

  5. Dependence on distribution partnersImpact: MediumLikelihood: High

    Sales execution relies on reseller and agent relationships that may not perform as expected.

    Exposure: NXC and other distribution agreements

  6. Intellectual property protectionImpact: MediumLikelihood: Low

    The company’s differentiation depends on protecting imaging technology and related know-how.

    ExposurePatentsSoftwareProprietary methods

Accounting

Judgemental items
Revenue recognition for hardware and services

Scanner sales are point-in-time, while training and maintenance are service-based.

Impact: Affects timing of reported revenue and gross margin

Fair value measurement of liabilities

Warrant, derivative, and earnout liabilities are revalued each period.

Impact: Can create large non-cash gains or losses in net income

Inventory and warranty estimates

Manufacturing, shipping, and replacement obligations require judgment.

Impact: Affects cost of revenue and reported gross profit

Quarterly revenue concentration

Small order counts can make period-to-period comparisons uneven.

Impact: Can cause volatility in revenue and operating results

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026